This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Riken Corporation. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2021
Title: Takafumi Wataya: Innovator in Stem Cell Research
Introduction
Takafumi Wataya is a prominent inventor based in Kobe, Japan, known for his significant contributions to the field of stem cell research. With a total of two patents to his name, he has made strides in developing methods that enhance the efficiency of stem cell culture.
Latest Patents
Wataya's latest patents focus on a method for the culture of stem cells. This innovative approach enables efficient suspension culture of stem cells in a serum-free medium. The method includes a step for quickly forming a homogenous aggregate of stem cells. It also provides techniques for selectively inducing the differentiation of nerves from stem cells, forming a cerebral cortical nerve network in vitro, and producing a steric structure of brain tissue in vitro. Additionally, it outlines a method for producing hypothalamic neuron progenitor cells by culturing pluripotent stem cells as suspended aggregates in a serum-free medium that does not contain various signal promoters and isolating the progenitor cells from the culture.
Career Highlights
Wataya is associated with Riken Corporation, where he continues to advance his research in stem cell technology. His work has garnered attention for its potential applications in regenerative medicine and neuroscience.
Collaborations
Throughout his career, Wataya has collaborated with notable colleagues, including Yoshiki Sasai and Mototsugu Eiraku. These partnerships have contributed to the development of innovative techniques in stem cell research.
Conclusion
Takafumi Wataya's contributions to stem cell research exemplify the impact of innovative thinking in the scientific community. His patents reflect a commitment to advancing medical science and improving therapeutic techniques.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
